KR20190121785A - 장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법 - Google Patents

장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20190121785A
KR20190121785A KR1020197026186A KR20197026186A KR20190121785A KR 20190121785 A KR20190121785 A KR 20190121785A KR 1020197026186 A KR1020197026186 A KR 1020197026186A KR 20197026186 A KR20197026186 A KR 20197026186A KR 20190121785 A KR20190121785 A KR 20190121785A
Authority
KR
South Korea
Prior art keywords
larazotide
derivative
subject
administering
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197026186A
Other languages
English (en)
Korean (ko)
Inventor
제이 마단
앤소니 브리크스라거
Original Assignee
이노베이트 바이오파마슈티컬스, 인코포레이티드
노쓰 캐롤라이나 스테이트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노베이트 바이오파마슈티컬스, 인코포레이티드, 노쓰 캐롤라이나 스테이트 유니버시티 filed Critical 이노베이트 바이오파마슈티컬스, 인코포레이티드
Publication of KR20190121785A publication Critical patent/KR20190121785A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197026186A 2017-02-10 2018-02-12 장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법 Ceased KR20190121785A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457279P 2017-02-10 2017-02-10
US62/457,279 2017-02-10
PCT/US2018/017813 WO2018148655A1 (en) 2017-02-10 2018-02-12 Compositions and methods for treating disease associated with permeability of intestinal epithelium

Publications (1)

Publication Number Publication Date
KR20190121785A true KR20190121785A (ko) 2019-10-28

Family

ID=63107916

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026186A Ceased KR20190121785A (ko) 2017-02-10 2018-02-12 장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (3) US11058902B2 (https=)
EP (2) EP3579862A4 (https=)
JP (1) JP2020507626A (https=)
KR (1) KR20190121785A (https=)
CN (1) CN110891587A (https=)
AU (1) AU2018219367A1 (https=)
BR (1) BR112019016705A2 (https=)
CA (1) CA3052975A1 (https=)
MX (1) MX2019009586A (https=)
WO (2) WO2018148655A1 (https=)
ZA (1) ZA201905439B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058902B2 (en) * 2017-02-10 2021-07-13 9 Meters Biopharma, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210100868A1 (en) * 2018-03-19 2021-04-08 North Carolina State University Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
WO2019183036A1 (en) 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
WO2021034629A1 (en) * 2019-08-16 2021-02-25 9 Meters Biopharma, Inc. Larazotide formulations
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids
WO2023154770A1 (en) * 2022-02-09 2023-08-17 9 Meters Biopharma, Inc. Compositions and methods for inhibiting rho kinase
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU2001249067A1 (en) 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
US20060062758A1 (en) * 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
US20090176244A1 (en) 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
CN101189518A (zh) * 2005-05-13 2008-05-28 马里兰巴尔的摩大学 评价治疗方案有效性的方法
AR057058A1 (es) * 2005-06-09 2007-11-14 Alba Therapeutics Corp Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
MX2008010221A (es) * 2006-02-09 2009-03-05 Alba Therapeutics Corp Formulaciones para un efector de union ajustada.
WO2008043107A2 (en) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20110201543A1 (en) 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
WO2009052489A2 (en) 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
CN101440369A (zh) * 2008-03-26 2009-05-27 华东师范大学 一种缺失的霍乱弧菌封闭带毒素的表达方法及应用
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
WO2010042821A1 (en) * 2008-10-10 2010-04-15 Nationwide Children's Hospital Method of treating necrotizing enterocolitis using heparin binding epidermal growth factor
EP3125870A4 (en) * 2014-04-04 2017-12-13 Alba Therapeutics Corporation Methods of treating celiac disease with larazotide
CA2955425A1 (en) * 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
US11058902B2 (en) * 2017-02-10 2021-07-13 9 Meters Biopharma, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium

Also Published As

Publication number Publication date
US20210299481A1 (en) 2021-09-30
EP3579862A1 (en) 2019-12-18
CN110891587A (zh) 2020-03-17
WO2018148655A1 (en) 2018-08-16
CA3052975A1 (en) 2018-08-16
ZA201905439B (en) 2021-02-24
EP3579863A4 (en) 2020-11-11
MX2019009586A (es) 2019-11-11
US20190358288A1 (en) 2019-11-28
BR112019016705A2 (pt) 2020-04-07
EP3579863A1 (en) 2019-12-18
US20190358289A1 (en) 2019-11-28
US11058902B2 (en) 2021-07-13
JP2020507626A (ja) 2020-03-12
WO2018148654A1 (en) 2018-08-16
AU2018219367A1 (en) 2019-09-19
EP3579862A4 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
KR20190121785A (ko) 장 상피의 투과성과 관련된 질환을 치료하기 위한 조성물 및 방법
Li et al. Beneficial effects of Dendrobium officinale on metabolic hypertensive rats by triggering the enteric-origin SCFA-GPCR43/41 pathway
CA3079627C (en) Pharmaceutical oral formulation comprising bacteria
JP7175990B2 (ja) 自己免疫疾患の予防または処置のための糞便物質
RS57431B1 (sr) Formulacija leka sa odloženim otpuštanjem
US20190262407A1 (en) Probiotic compositions and methods of use thereof
JP6895752B2 (ja) ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
JPWO1995028963A1 (ja) 結腸特異的薬物放出システム
CN117398392A (zh) 一种调节肠道微生物群的治疗方法
CN114514031A (zh) 拉拉唑肽制剂
JP7700109B2 (ja) 胃腸の健康組成物
US20210100868A1 (en) Compositions and methods for treating or preventing gastrointestinal damage associated with nsaid therapy
KR20170122776A (ko) 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
CN105744947A (zh) 用于治疗与细菌侵入相关的ibd的乳铁蛋白
KR20230005209A (ko) D-아미노산을 포함하는 라라조타이드 유도체
KR20250022799A (ko) 비타민 c와 비피도박테리움 아니말리스 아종 락티스를 포함하는 조합물
WO2023237674A1 (en) Vitamin b2 for use in improving gut health
NL2021365B1 (en) Fecal matter for prevention or treatment of autoimmune diseases
CA2974055A1 (en) A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
KR20250022163A (ko) 비타민 c와 비피도박테리움 아니말리스 아종 락티스를 포함하는 조합물
TW201513866A (zh) 低劑量藥物組合物
HK40000727A (en) Treatment for modulating gut microbiota

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190905

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210122

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230421

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230421

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I